PRINCETON, NJ, May 22, 2014: Agile Therapeutics, Inc., a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced the pricing of its initial public offering of 9,166,667 shares of its common stock at a public offering price of $6.00 per share. Agile Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 1,375,000 additional shares of common stock at the initial public offering price to cover any over-allotments. The shares are expected to begin trading on the NASDAQ Global Market, beginning on May 23, 2014, under the symbol "AGRX." The offering is expected to close on May 29, 2014, subject to customary closing conditions.
Morgan Lewis serves as Agile Therapeutics’s legal adviser on the offering led by Business and Finance partners Steven Cohen and Emilio Ragosa and including associate Bryan Keighery. Also assisting on the offering are FDA Practice partner Kathleen Sanzo, Intellectual Property Practice partners Louis Beardell and James Sims and Employee Benefits and Executive Compensation Practice partner Amy Pocino Kelly and of counsel Heather Brookfield.
For further information about the offering, please see the Agile Therapeutics press release.